Full Press Release Details
ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced they are entering into a strategic platform license (SPL) with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.
Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.
TG Therapeutics entered into an agreement with Precision BioSciences, Inc. and acquired a worldwide license to Precision’s Azercabtagene Zapreleucel (azer-cel), an investigational allogeneic or “off the shelf” CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications. TG received clearance by the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application for azer-cel in progressive forms of multiple sclerosis (MS) and is targeting commencement of a Phase 1 trial in 2025.
“By leveraging our commercially validated cell-engineering platform and optimized T cell manufacturing workflow, TG Therapeutics is advancing toward their Phase 1 clinical trial for the application of azer-cel in progressive forms of MS,” said Maher Masoud, President and CEO of MaxCyte. “Our technology has been integral to the manufacturing of allogeneic T cell immunotherapies and was efficiently transferred from Precision BioSciences when TG Therapeutics obtained global rights for azer-cel for autoimmune diseases in January 2024. With our new partnership, we will continue to support the development of azer-cel to expand the application to autoimmune diseases.”
MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically and commercially validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency and cell viability, seamless scalability and enhanced functionality, the ExPERT™ platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics.
About TG Therapeutics
Nominated Adviser and Joint Corporate Broker
Emma Earl / Freddy Crossley
TG Therapeutics Contact:
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Email: media@tgtxinc.com
Telephone: +1 877-575-TGTX (8489), Option 6
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 12, 2024, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.